Mineralys Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mineralys Therapeutics generated cash of -$81,173,000, which is less than the previous year. Cash used in financing activities reached the amount of $203,248,000 last year. Net change in cash is therefore -$38,397,000.
Cash Flow
| 2020 | -2.46M | 0 | 3.83M |
|---|---|---|---|
| 2021 | -14.55M | 0 | 23.81M |
| 2022 | -29.22M | -21.75M | 128.01M |
| 2023 | -81.17M | -160.47M | 203.24M |
MLYS Cash Flow Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Cash at beginning of period | 87.70M | 10.66M | 1.40M | 42K |
Operating activities | ||||
Net income | -71.89M | -29.79M | -19.40M | -3.42M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||
Depreciation and amortization | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 5.06M | 455K | 80K | 1K |
| Deferred income tax benefit | 5.06M | 455K | 80K | 1K |
| Changes in operating assets and liabilities: | ||||
Accounts receivable, net | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 3.01M | 0 | 0 |
Cash generated by operating activities | -81.17M | -29.22M | -14.55M | -2.46M |
Investing activities | ||||
Purchases Of Investments | -347.97M | -71.75M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -160.47M | -21.75M | 0 | 0 |
Financing activities | ||||
Common Stock Issued | 202.99M | 0 | 23.81M | -20K |
Payments for dividends | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -1.62M | 0 | -20K |
Repayments of term debt | 0 | 0 | 0 | -3.85M |
Cash used in financing activities | 203.24M | 128.01M | 23.81M | 3.83M |
Net Change In Cash | -38.39M | 77.03M | 9.25M | 1.36M |
Cash at end of period | 49.30M | 87.70M | 10.66M | 1.40M |
| Data source | Data source |